How many clinical trials are tracked of galcanezumab?

18 trials are tracked, 10 with published results.

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine OB/GYN & Women's Health Orthopedics & Sports Medicine Genetics & Precision Medicine Radiology & Imaging Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Urology Hematology Dermatology Ophthalmology Emergency Medicine Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Questions

Text Size

galcanezumab

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of galcanezumab

18 trials tracked of galcanezumab: 12 in phase 3 or 4 and 10 with published results. The most-cited published study has 256 citations.

18Trials tracked

12Phase 3 & 4

0Recruiting

10With published results

Phase distribution

Phase 4 3 Phase 3 9 Phase 2 2 Phase 1 4

Phase 3 A Study Of Galcanezumab In Participants With Episodic Cluster Headache Completed · 256 cited
Phase 3 A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura Completed · 141 cited
Phase 4 A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine Completed · 43 cited
Phase 3 Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study Completed · 43 cited
Phase 3 Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study Completed · 43 cited
Phase 3 Evaluation of Galcanezumab in the Prevention of Chronic Migraine Completed · 42 cited

Show 12 more trials

Phase 3 A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine Completed · 37 cited
Phase 3 A Study of LY2951742 (Galcanezumab) in Japanese Participants With Migraine Completed · 32 cited
Phase 3 A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache Completed · 17 cited
Phase 3 A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine Completed · 16 cited
Phase 4 A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist Completed
Phase 4 Anti-CGRP for Inflammation and Pain Modulation in Small Fiber Neuropathy/Fibromyalgia Completed
Phase 2 A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache Completed
Phase 2 A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic Migraine Completed
Phase 1 Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine Completed
Phase 1 A Study of Galcanezumab in Healthy Participants Completed
Phase 1 A Study of Galcanezumab (LY2951742) in Healthy Chinese Participants Completed
Phase 1 A Study of Galcanezumab in Healthy Participants. Completed

Showing the 18 most-cited and recently-updated of 18 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.